375 related articles for article (PubMed ID: 33763903)
1. Nondermatophyte mould onychomycosis.
Gupta AK; Summerbell RC; Venkataraman M; Quinlan EM
J Eur Acad Dermatol Venereol; 2021 Aug; 35(8):1628-1641. PubMed ID: 33763903
[TBL] [Abstract][Full Text] [Related]
2. Itraconazole and terbinafine treatment of some nondermatophyte molds causing onychomycosis of the toes and a review of the literature.
Gupta AK; Gregurek-Novak T; Konnikov N; Lynde CW; Hofstader S; Summerbell RC
J Cutan Med Surg; 2001; 5(3):206-10. PubMed ID: 11685666
[TBL] [Abstract][Full Text] [Related]
3. A comprehensive review of nondermatophyte mould onychomycosis: Epidemiology, diagnosis and management.
Gupta AK; Wang T; Cooper EA; Summerbell RC; Piguet V; Tosti A; Piraccini BM
J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):480-495. PubMed ID: 38010049
[TBL] [Abstract][Full Text] [Related]
4. Randomized, double-blind, comparative study on efficacy and safety of itraconazole pulse therapy and terbinafine pulse therapy on nondermatophyte mold onychomycosis: A study with 90 patients.
Ranawaka RR; Nagahawatte A; Gunasekara TA; Weerakoon HS; de Silva SH
J Dermatolog Treat; 2016 Aug; 27(4):364-72. PubMed ID: 26651495
[TBL] [Abstract][Full Text] [Related]
5. [Onychocola canadensis Sigler in onychomycosis : A new dermatophyte-like mould in Germany].
Nenoff P; Schorlemmer B; Uhrlaß S; Baunacke A; Baunacke A; Friedrichs C; Iffländer J; Syhre E; Schneider A; Krüger C; Maier T
Hautarzt; 2016 Sep; 67(9):739-49. PubMed ID: 26758910
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of itraconazole, terbinafine, fluconazole, griseofulvin and ketoconazole in the treatment of Scopulariopsis brevicaulis causing onychomycosis of the toes.
Gupta AK; Gregurek-Novak T
Dermatology; 2001; 202(3):235-8. PubMed ID: 11385230
[TBL] [Abstract][Full Text] [Related]
7. Continuous terbinafine and pulse itraconazole for the treatment of non-dermatophyte mold toenail onychomycosis.
Shemer A; Gupta AK; Kamshov S; Babaev M; Hermush V; Farhi R; Daniel CR; Foley KA
J Dermatolog Treat; 2021 May; 32(3):310-313. PubMed ID: 31415182
[TBL] [Abstract][Full Text] [Related]
8. A risk-benefit assessment of the newer oral antifungal agents used to treat onychomycosis.
Gupta AK; Shear NH
Drug Saf; 2000 Jan; 22(1):33-52. PubMed ID: 10647975
[TBL] [Abstract][Full Text] [Related]
9. Itraconazole therapy is effective for pedal onychomycosis caused by some nondermatophyte molds and in mixed infection with dermatophytes and molds: a multicenter study with 36 patients.
De Doncker PR; Scher RK; Baran RL; Decroix J; Degreef HJ; Roseeuw DI; Havu V; Rosen T; Gupta AK; Piérard GE
J Am Acad Dermatol; 1997 Feb; 36(2 Pt 1):173-7. PubMed ID: 9039163
[TBL] [Abstract][Full Text] [Related]
10. Systematic review of nondermatophyte mold onychomycosis: diagnosis, clinical types, epidemiology, and treatment.
Gupta AK; Drummond-Main C; Cooper EA; Brintnell W; Piraccini BM; Tosti A
J Am Acad Dermatol; 2012 Mar; 66(3):494-502. PubMed ID: 21820203
[TBL] [Abstract][Full Text] [Related]
11. [Diagnosis of non dermatophyte onychomycosis ant its relevance for treatment].
Monod M; Lurati M; Baudraz-Rosselet F
Rev Med Suisse; 2013 Apr; 9(380):730-3. PubMed ID: 23621043
[TBL] [Abstract][Full Text] [Related]
12. An open randomized comparative study of oral itraconazole pulse and terbinafine pulse in the treatment of onychomycosis.
Mishra M; Panda P; Tripathy S; Sengupta S; Mishra K
Indian J Dermatol Venereol Leprol; 2005; 71(4):262-6. PubMed ID: 16394436
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of antifungal agents in onychomycoses.
Debruyne D; Coquerel A
Clin Pharmacokinet; 2001; 40(6):441-72. PubMed ID: 11475469
[TBL] [Abstract][Full Text] [Related]
14. Efficacious treatment of non-dermatophyte mould onychomycosis with topical amphotericin B.
Lurati M; Baudraz-Rosselet F; Vernez M; Spring P; Bontems O; Fratti M; Monod M
Dermatology; 2011; 223(4):289-92. PubMed ID: 22236569
[TBL] [Abstract][Full Text] [Related]
15. Successful treatment of resistant onychomycosis with voriconazole in a liver transplant patient.
Nofal A; Fawzy MM; El-Hawary EE
Dermatol Ther; 2020 Nov; 33(6):e14014. PubMed ID: 32667111
[TBL] [Abstract][Full Text] [Related]
16. Comparison of in vitro antifungal activities of efinaconazole and currently available antifungal agents against a variety of pathogenic fungi associated with onychomycosis.
Jo Siu WJ; Tatsumi Y; Senda H; Pillai R; Nakamura T; Sone D; Fothergill A
Antimicrob Agents Chemother; 2013 Apr; 57(4):1610-6. PubMed ID: 23318803
[TBL] [Abstract][Full Text] [Related]
17. Onychomycosis: a review.
Gupta AK; Stec N; Summerbell RC; Shear NH; Piguet V; Tosti A; Piraccini BM
J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):1972-1990. PubMed ID: 32239567
[TBL] [Abstract][Full Text] [Related]
18. Fusarium onychomycosis: prevalence, clinical presentations, response to itraconazole and terbinafine pulse therapy, and 1-year follow-up in nine cases.
Ranawaka RR; Nagahawatte A; Gunasekara TA
Int J Dermatol; 2015 Nov; 54(11):1275-82. PubMed ID: 26223159
[TBL] [Abstract][Full Text] [Related]
19. Onychomycosis: modern diagnostic and treatment approaches.
Tchernev G; Penev PK; Nenoff P; Zisova LG; Cardoso JC; Taneva T; Ginter-Hanselmayer G; Ananiev J; Gulubova M; Hristova R; Nocheva D; Guarneri C; Martino G; Kanazawa N
Wien Med Wochenschr; 2013 Jan; 163(1-2):1-12. PubMed ID: 23053563
[TBL] [Abstract][Full Text] [Related]
20. In vitro antifungal susceptibility testing of fungi in patients with onychomycosis.
Abu El-Hamd M; Abd Elhameed MI; Shalaby MFM; Saleh R
Dermatol Ther; 2020 May; 33(3):e13429. PubMed ID: 32304603
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
